相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Randomized Phase II Trial of Irinotecan/Docetaxel or Irinotecan/Docetaxel Plus Cetuximab for Metastatic Pancreatic Cancer An Eastern Cooperative Oncology Group Study
Barbara Burtness et al.
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS (2016)
Cancer Statistics, 2016
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2016)
The Landscape of Pancreatic Cancer Therapeutic Resistance Mechanisms
Saswati Chand et al.
INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES (2016)
Metastatic Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline
Davendra P. S. Sohal et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial
Andrea Wang-Gillam et al.
LANCET (2016)
Genomic analyses identify molecular subtypes of pancreatic cancer
Peter Bailey et al.
NATURE (2016)
PD-L1 expression in human cancers and its association with clinical outcomes
Xin Wang et al.
ONCOTARGETS AND THERAPY (2016)
From bench to bedside a comprehensive review of pancreatic cancer immunotherapy
Paul R. Kunk et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2016)
A phase 3 randomized, double-blind, placebo-controlled trial of ganitumab or placebo in combination with gemcitabine as first-line therapy for metastatic adenocarcinoma of the pancreas: the GAMMA trial
C. S. Fuchs et al.
ANNALS OF ONCOLOGY (2015)
SPARC Expression Did Not Predict Efficacy of nab-Paclitaxel plus Gemcitabine or Gemcitabine Alone for Metastatic Pancreatic Cancer in an Exploratory Analysis of the Phase III MPACT Trial
Manuel Hidalgo et al.
CLINICAL CANCER RESEARCH (2015)
Randomized Phase II Trial of Gemcitabine Plus TH-302 Versus Gemcitabine in Patients With Advanced Pancreatic Cancer
Mitesh J. Borad et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Randomized Phase Ib/II Study of Gemcitabine Plus Placebo or Vismodegib, a Hedgehog Pathway Inhibitor, in Patients With Metastatic Pancreatic Cancer
Daniel V. T. Catenacci et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Carboxylesterase 2 as a Determinant of Response to Irinotecan and Neoadjuvant FOLFIRINOX Therapy in Pancreatic Ductal Adenocarcinoma
Michela Capello et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2015)
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
D. T. Le et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Carboxylesterase 2 as a Determinant of Response to Irinotecan and Neoadjuvant FOLFIRINOX Therapy in Pancreatic Ductal Adenocarcinoma
Michela Capello et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2015)
Targeting self-renewal pathways in cancer stem cells: clinical implications for cancer therapy
A. Borah et al.
ONCOGENESIS (2015)
Risk factors for pancreatic cancer: a summary review of meta-analytical studies
Patrick Maisonneuve et al.
INTERNATIONAL JOURNAL OF EPIDEMIOLOGY (2015)
European cancer mortality predictions for the year 2014
M. Malvezzi et al.
ANNALS OF ONCOLOGY (2014)
Dose escalation to rash for erlotinib plus gemcitabine for metastatic pancreatic cancer: the phase II RACHEL study
E. Van Cutsem et al.
BRITISH JOURNAL OF CANCER (2014)
Oncogenic KRAS signalling in pancreatic cancer
S. Eser et al.
BRITISH JOURNAL OF CANCER (2014)
A randomized phase I/II study of everolimus, irinotecan, and cetuximab versus capecitabine and oxaliplatin in gemcitabine-resistant patients with pancreatic cancer
Jon Kroll Bjerregaard et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Pancreatic Adenocarcinoma
David P. Ryan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
WNT7B mediates autocrine Wnt/β-catenin signaling and anchorage-independent growth in pancreatic adenocarcinoma
M. D. Arensman et al.
ONCOGENE (2014)
Efficacy of nimotuzumab plus gemcitabine usage as first-line treatment in patients with advanced pancreatic cancer
Dan Su et al.
TUMOR BIOLOGY (2014)
Prognostic significance of WNT signaling in pancreatic ductal adenocarcinoma
Mitsuhiro Nakamoto et al.
VIRCHOWS ARCHIV (2014)
Multicenter phase II trial to investigate safety and efficacy of gemcitabine combined with cetuximab as adjuvant therapy in pancreatic cancer (ATIP)
H. Fensterer et al.
ANNALS OF ONCOLOGY (2013)
Global, multicenter, randomized, phase II trial of gemcitabine and gemcitabine plus AGS-1C4D4 in patients with previously untreated, metastatic pancreatic cancer
B. M. Wolpin et al.
ANNALS OF ONCOLOGY (2013)
Randomised, placebo-controlled, double-blind, parallel-group phase III study evaluating aflibercept in patients receiving first-line treatment with gemcitabine for metastatic pancreatic cancer
Philippe Rougier et al.
EUROPEAN JOURNAL OF CANCER (2013)
FOLFIRINOX for locally advanced and metastatic pancreatic cancer: single institution retrospective review of efficacy and toxicity
Krishna S. Gunturu et al.
MEDICAL ONCOLOGY (2013)
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
Daniel D. Von Hoff et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Targeting CXCL12 from FAP-expressing carcinomaassociated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer
Christine Feig et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
IGF-1R as an anti-cancer target-trials and tribulations
Helen X. Chen et al.
CHINESE JOURNAL OF CANCER (2013)
Phase II Study of Gemcitabine, Oxaliplatin, and Cetuximab in Advanced Pancreatic Cancer
Jaime R. Merchan et al.
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS (2012)
A randomized, placebo-controlled phase 2 study of ganitumab (AMG 479) or conatumumab (AMG 655) in combination with gemcitabine in patients with metastatic pancreatic cancer
H. L. Kindler et al.
ANNALS OF ONCOLOGY (2012)
BAYPAN study: a double-blind phase III randomized trial comparing gemcitabine plus sorafenib and gemcitabine plus placebo in patients with advanced pancreatic cancer
A. Goncalves et al.
ANNALS OF ONCOLOGY (2012)
Multicentre phase II trial of trastuzumab and capecitabine in patients with HER2 overexpressing metastatic pancreatic cancer
J. Harder et al.
BRITISH JOURNAL OF CANCER (2012)
Fractionated Radioimmunotherapy With 90Y-Clivatuzumab Tetraxetan and Low-Dose Gemcitabine Is Active in Advanced Pancreatic Cancer
Allyson J. Ocean et al.
CANCER (2012)
A phase II randomized study of cetuximab and bevacizumab alone or in combination with gemcitabine as first-line therapy for metastatic pancreatic adenocarcinoma
Andrew H. Ko et al.
INVESTIGATIONAL NEW DRUGS (2012)
Phase I randomized phase II trial of gemcitabine, erlotinib, and cixutumumab versus gemcitabine plus erlotinib as first-line treatment in patients with metastatic pancreatic cancer (SWOG-0727).
Philip Agop Philip et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
RNA sequencing of pancreatic circulating tumour cells implicates WNT signalling in metastasis
Min Yu et al.
NATURE (2012)
Safety and Activity of Anti-PD-L1 Antibody in Patients with Advanced Cancer
Julie R. Brahmer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Hypoxia activates the hedgehog signaling pathway in a ligand-independent manner by upregulation of Smo transcription in pancreatic cancer
Hideya Onishi et al.
CANCER SCIENCE (2011)
Treatment of Advanced Pancreatic Carcinoma with 90Y-Clivatuzumab Tetraxetan: A Phase I Single-Dose Escalation Trial
Seza A. Gulec et al.
CLINICAL CANCER RESEARCH (2011)
Randomized phase II trial of panitumumab, erlotinib, and gemcitabine (PGE) versus erlotinib-gemcitabine (GE) in patients with untreated, metastatic pancreatic adenocarcinoma.
G. P. Kim et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Gemcitabine Plus nab-Paclitaxel Is an Active Regimen in Patients With Advanced Pancreatic Cancer: A Phase I/II Trial
Daniel D. Von Hoff et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Axitinib plus gemcitabine versus placebo plus gemcitabine in patients with advanced pancreatic adenocarcinoma: a double-blind randomised phase 3 study
Hedy L. Kindler et al.
LANCET ONCOLOGY (2011)
FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
Thierry Conroy et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
A phase II study of bevacizumab plus erlotinib for gemcitabine-refractory metastatic pancreatic cancer
Andrew H. Ko et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2010)
Gemcitabine Plus Bevacizumab Compared With Gemcitabine Plus Placebo in Patients With Advanced Pancreatic Cancer: Phase III Trial of the Cancer and Leukemia Group B (CALGB 80303)
Hedy Lee Kindler et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Phase III Study Comparing Gemcitabine Plus Cetuximab Versus Gemcitabine in Patients With Advanced Pancreatic Adenocarcinoma: Southwest Oncology Group-Directed Intergroup Trial S0205
Philip A. Philip et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Phase 2 Trial of Single Agent Ipilimumab (Anti-CTLA-4) for Locally Advanced or Metastatic Pancreatic Adenocarcinoma
Richard E. Royal et al.
JOURNAL OF IMMUNOTHERAPY (2010)
Insulin receptor functionally enhances multistage tumor progression and conveys intrinsic resistance to IGF-1R targeted therapy
Danielle B. Ulanet et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Human Equilibrative Nucleoside Transporter 1 (hENT1) in Pancreatic Adenocarcinoma: Towards Individualized Treatment Decisions
Jennifer L. Spratlin et al.
Cancers (2010)
Randomised Phase I/II trial assessing the safety and efficacy of radiolabelled anti-carcinoembryonic antigen I131 KAb201 antibodies given intra-arterially or intravenously in patients with unresectable pancreatic adenocarcinoma
Asma Sultana et al.
BMC CANCER (2009)
Expression of the costimulatory molecule B7-H3 is associated with prolonged survival in human pancreatic cancer
Martin Loos et al.
BMC CANCER (2009)
Bevacizumab combined with gemcitabine and capecitabine for advanced pancreatic cancer: a phase II study
M. Javle et al.
BRITISH JOURNAL OF CANCER (2009)
HER2 overexpression correlates with survival after curative resection of pancreatic cancer
Masahiro Komoto et al.
CANCER SCIENCE (2009)
Ex vivo expanded telomerase-specific T cells are effective in an orthotopic mouse model for pancreatic adenocarcinoma
H. Hassanin et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2009)
Inhibition of γ-Secretase Activity Inhibits Tumor Progression in a Mouse Model of Pancreatic Ductal Adenocarcinoma
Ruben Plentz et al.
GASTROENTEROLOGY (2009)
Phase II Study of Bevacizumab With Concurrent Capecitabine and Radiation Followed by Maintenance Gemcitabine and Bevacizumab for Locally Advanced Pancreatic Cancer: Radiation Therapy Oncology Group RTOG 0411
Christopher H. Crane et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Phase III Trial of Bevacizumab in Combination With Gemcitabine and Erlotinib in Patients With Metastatic Pancreatic Cancer
Eric Van Cutsem et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
A phase II study evaluating bevacizumab in combination with fixed-dose rate gemcitabine and low-dose cisplatin for metastatic pancreatic cancer: is an anti-VEGF strategy still applicable?
Andrew H. Ko et al.
INVESTIGATIONAL NEW DRUGS (2008)
Final analysis of a randomized phase II study of bevacizumab (B) and gemcitabine (G) plus cetuximab (C) or erlotinib (E) in patients (pts) with advanced pancreatic cancer (PC)
H. L. Kindler et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Efficacy of gemcitabine plus axitinib compared with gemcitabine alone in patients with advanced pancreatic cancer:: an open-label randomised phase II study
Jean-Philippe Spano et al.
LANCET (2008)
Cetuximab plus gemcitabine and cisplatin compared with gemcitabine and cisplatin alone in patients with advanced pancreatic cancer: a randomised, multicentre, phase II trial
[Anonymous]
LANCET ONCOLOGY (2008)
Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses
Manish J. Butte et al.
IMMUNITY (2007)
Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: A phase III trial of the National Cancer Institute of Canada clinical trials group
Malcolm J. Moore et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer - A Randomized controlled trial
Helmut Oettle et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2007)
Disrupting insulin-like growth factor signaling as a potential cancer therapy
Deepali Sachdev et al.
MOLECULAR CANCER THERAPEUTICS (2007)
Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer
Volker Heinemann et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Phase I study of the humanised anti-EGFR monoclonal antibody matuzumab (EMD 72000) combined with gemcitabine in advanced pancreatic cancer
U Graeven et al.
BRITISH JOURNAL OF CANCER (2006)
Epidermal growth factor receptor expression in pancreatic carcinoma using tissue microarray technique
Mark Bloomston et al.
DIGESTIVE SURGERY (2006)
The Notch pathway in cancer:: Differentiation gone awry
J Sjölund et al.
EUROPEAN JOURNAL OF CANCER (2005)
Phase II trial of bevacizurnab plus gemcitabine in patients with advanced pancreatic cancer
HL Kindler et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Copy number of chromosome 17 but not HER2 amplification predicts clinical outcome of patients with pancreatic ductal adenocarcinoma
NH Stoecklein et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer: A multicenter phase II trial
HQ Xiong et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Herceptin and gemcitabine for metastatic pancreatic cancers that overexpress HER-2/neu
H Safran et al.
CANCER INVESTIGATION (2004)
Coexpression of IGF-1R and c-Src proteins in human pancreatic ductal adenocarcinoma
A Hakam et al.
DIGESTIVE DISEASES AND SCIENCES (2003)
Overexpression of the HER-2/neu oncogene in pancreatic adenocarcinoma
H Safran et al.
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS (2001)
分享论文
